新生児トキシコロジーの世界市場

新生児トキシコロジーの世界市場は2030年までに4億6,180万米ドルに達する見込み

2024年に2億7,320万米ドルと推定される新生児トキシコロジーの世界市場は、2030年には4億6,180万米ドルに達し、分析期間2024-2030年のCAGRは9.1%で成長すると予測されます。本レポートで分析したセグメントの1つである糞便は、CAGR 7.6%を記録し、分析期間終了時には1億9,280万米ドルに達すると予測されています。尿セグメントの成長率は、分析期間でCAGR 11.1％と推定されます。

米国市場は7,440万米ドルと推定、中国はCAGR12.3％で成長予測

米国の新生児トキシコロジー市場は2024年に7,440万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに9,210万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは12.3%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ6.7%と7.9%と予測されています。欧州では、ドイツがCAGR約7.1%で成長すると予測されています。

世界の新生児トキシコロジー市場- 主要動向と促進要因のまとめ

新生児トキシコロジーは乳幼児ヘルスケアをどのように形成しているか？

新生児トキシコロジーは、新生児の毒性曝露の理解、診断、管理に焦点を当てた進化する医学分野です。新生児期は代謝・排泄システムが未熟なため非常に敏感であり、毒素、薬剤、環境汚染物質に対して特に脆弱です。新生児トキシコロジーは、母親の薬物使用、出生前の環境暴露、出生後の有害物質との接触から生じる悪影響を予防・軽減する上で重要な役割を果たします。新生児トキシコロジーにおける一般的な懸念事項には、母親の薬物乱用による胎内薬物曝露、新生児疾患のために投与される薬剤の毒性影響、重金属、農薬、内分泌かく乱物質などの環境汚染物質が含まれます。母親のオピオイド使用により乳児が禁断症状を起こす新生児禁断症状（NAS）の場合、新生児毒物学者は効果的な治療プロトコルを開発し、実施する使命を担っています。調査手法の進歩によりスクリーニング方法が改善され、臍帯血、胎便、新生児尿中の毒素を早期に検出できるようになりました。さらに、革新的な薬物動態学的研究により、新生児への薬物投与が改良され、抗生物質、抗けいれん薬、鎮痛薬などの薬物による毒性のリスクが減少しています。この分野の研究が拡大するにつれ、新生児トキシコロジーは母子保健の重要な要素になりつつあり、世界中で政策決定を導き、臨床実践を形成しています。

新生児トキシコロジーの主な課題は？

新生児トキシコロジーの進歩にもかかわらず、いくつかの課題が新生児の毒性曝露の効果的な診断と管理の妨げとなっています。最大の課題のひとつは、新生児に特化した薬理学的データが限られていることです。臨床薬物試験では、倫理的な懸念から妊婦や新生児が除外されることが多いからです。このような包括的な新生児薬物動態学的および薬力学的研究の欠如は、正確な薬物投与量と安全性ガイドラインを確立することを困難にしています。もう一つの大きな問題は、特にオピオイドやその他の薬物危機に見舞われている地域で、新生児への薬物曝露が増加していることです。新生児禁断症状は、入院期間の延長、ヘルスケアコストの増加、長期的な神経発達合併症につながり、懸念が高まっています。さらに、鉛、水銀、内分泌攪乱化学物質などの環境毒素は、新生児の健康に長期的なリスクをもたらし、神経発達障害、代謝異常、免疫系異常などの症状を引き起こします。標準化された新生児トキシコロジースクリーニングが普遍的に実施されていないため、これらの毒素の検出は依然として困難です。さらに、専門的な新生児トキシコロジーケアへのアクセスにおける格差が、特にヘルスケアインフラが限られている低資源環境において、効果的な管理の障壁となっています。これらの課題に対処するためには、毒物学的スクリーニングプログラムの強化、治療へのアクセスの改善、新生児に特化したより安全な薬物療法の開発など、多方面からのアプローチが必要です。

新技術は新生児トキシコロジーに革命を起こせるか？

新生児トキシコロジー市場は、発見、診断、治療結果の改善を目的とした技術的進歩の波を目の当たりにしています。最も重要な技術革新のひとつは、新生児生体サンプル中の有害物質を迅速に同定できるハイスループット・スクリーニング法の開発です。液体クロマトグラフィー質量分析計（LC-MS）やガスクロマトグラフィー質量分析計（GC-MS）は、精密な毒物学的分析にますます使用されるようになっており、胎内薬物曝露や環境汚染の場合、早期介入を可能にしています。もうひとつの画期的な進歩は、乾燥血液スポット分析や呼気ベースのバイオマーカーなど、新生児の不快感を最小限に抑えながら重要な診断情報を提供する、非侵襲的な毒物学的スクリーニング技術の導入です。人工知能と機械学習も新生児トキシコロジーに統合され、新生児の薬物代謝と毒性曝露リスクの予測モデルが強化されています。さらに、新生児薬理ゲノミクスの進歩が個別化医療への道を開き、新生児の薬物投与を最適化し、副作用を最小限に抑えます。デジタルヘルスプラットフォームと遠隔モニタリング技術は新生児トキシコロジーをさらにサポートし、新生児の健康指標と毒性曝露マーカーのリアルタイム追跡を可能にしています。このような技術革新が新生児医療の形を変え続けているため、新生児トキシコロジーの転帰を改善する可能性が拡大し、新生児の有害物質曝露をより安全かつ効果的に管理するための新たな希望がもたらされています。

新生児トキシコロジー市場の成長の原動力は？

新生児トキシコロジー市場の成長は、新生児の物質曝露の有病率の増加、環境毒素に対する意識の高まり、診断・治療技術の進歩など、いくつかの要因によってもたらされます。妊娠中のオピオイド中毒や薬物乱用の世界の増加が新生児トキシコロジーサービスの需要を煽り、ヘルスケアプロバイダーは影響を受けた新生児のスクリーニングや治療戦略の改善を求めています。出生前スクリーニングプログラムの強化や新生児離脱管理プロトコルなど、新生児薬物曝露対策に向けた政府の取り組みも市場拡大を後押ししています。環境衛生とそれが新生児の発育に及ぼす影響に重点が置かれるようになったことで、出生前および出生後の有害物質曝露に対処する研究や規制措置が増加しています。さらに、新生児集中治療室（NICU）や小児毒物学専門センターの拡大も市場拡大に寄与しています。次世代毒物学スクリーニング・プラットフォームやAIを活用した新生児リスク評価ツールなどの技術の進歩は、診断精度と治療効率を高めています。さらに、製薬会社、ヘルスケア機関、研究機関の協力関係の強化が、より安全な新生児用薬剤や治療プロトコルの開発を促進しています。新生児トキシコロジーが進化を続ける中、新生児の健康を守る上での役割はより顕著になり、市場の持続的な成長を促し、新生児ヘルスケアの未来を形成しています。

セグメント

検体タイプ（糞便、尿、臍帯、その他の検体タイプ）、技術タイプ（質量分析技術、免疫測定技術）、薬物タイプ（カンナビノイド、オピオイド、コカイン、ベンゾジアゼピン、アンフェタミン、その他の違法薬物タイプ）、エンドユーザー（臨床検査室エンドユーザー、病院エンドユーザー、その他のエンドユーザー）

調査対象企業の例

• Agilent Technologies, Inc.
• ARUP Laboratories
• Bio-Rad Laboratories, Inc.
• Charles River Laboratories
• Cordant Health Solutions
• Covance Inc.
• ERBC Group
• Eurofins Scientific
• ICON plc
• Labcorp
• Medpace Holdings, Inc.
• NMS Labs
• Omega Laboratories, Inc.
• Parexel International Corporation
• PPD, Inc.
• PRA Health Sciences
• Quest Diagnostics Incorporated
• Syneos Health
• USDTL（United States Drug Testing Laboratories, Inc.）
• WuXi AppTec

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Neonatal Toxicology Market to Reach US$461.8 Million by 2030

The global market for Neonatal Toxicology estimated at US$273.2 Million in the year 2024, is expected to reach US$461.8 Million by 2030, growing at a CAGR of 9.1% over the analysis period 2024-2030. Meconium, one of the segments analyzed in the report, is expected to record a 7.6% CAGR and reach US$192.8 Million by the end of the analysis period. Growth in the Urine segment is estimated at 11.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$74.4 Million While China is Forecast to Grow at 12.3% CAGR

The Neonatal Toxicology market in the U.S. is estimated at US$74.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$92.1 Million by the year 2030 trailing a CAGR of 12.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.7% and 7.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.1% CAGR.

Global Neonatal Toxicology Market - Key Trends & Drivers Summarized

How Is Neonatal Toxicology Shaping Infant Healthcare?

Neonatal toxicology is an evolving field of medical science that focuses on understanding, diagnosing, and managing toxic exposure in newborns. The neonatal period is highly sensitive due to immature metabolic and excretory systems, making infants particularly vulnerable to toxins, medications, and environmental pollutants. Neonatal toxicology plays a crucial role in preventing and mitigating adverse effects arising from maternal drug use, prenatal environmental exposures, and postnatal contact with harmful substances. Common concerns in neonatal toxicology include in-utero drug exposure due to maternal substance abuse, toxic effects of medications administered for neonatal conditions, and environmental contaminants such as heavy metals, pesticides, and endocrine disruptors. In cases of neonatal abstinence syndrome (NAS), where infants experience withdrawal symptoms due to maternal opioid use, neonatal toxicologists are tasked with developing and implementing effective treatment protocols. Advancements in neonatal toxicology have led to improved screening methodologies, allowing for the early detection of toxins in umbilical cord blood, meconium, and neonatal urine. Additionally, innovative pharmacokinetic studies are helping refine neonatal drug dosing, reducing the risk of toxicity from medications such as antibiotics, anticonvulsants, and analgesics. As research in this field expands, neonatal toxicology is becoming a critical component of maternal and infant health, guiding policy decisions and shaping clinical practices worldwide.

What Are the Major Challenges in Neonatal Toxicology?

Despite advancements in neonatal toxicology, several challenges continue to hinder the effective diagnosis and management of toxic exposures in newborns. One of the biggest challenges is the limited availability of neonatal-specific pharmacological data, as clinical drug trials often exclude pregnant women and neonates due to ethical concerns. This lack of comprehensive neonatal pharmacokinetic and pharmacodynamic studies makes it difficult to establish precise drug dosages and safety guidelines. Another major issue is the rising incidence of neonatal substance exposure, particularly in regions experiencing opioid and other drug crises. Neonatal abstinence syndrome has become a growing concern, leading to extended hospital stays, increased healthcare costs, and long-term neurodevelopmental complications. Additionally, environmental toxins such as lead, mercury, and endocrine-disrupting chemicals pose long-term risks to neonatal health, contributing to conditions such as neurodevelopmental disorders, metabolic abnormalities, and immune system dysregulation. The detection of these toxins remains challenging, as standardized neonatal toxicology screening is not universally implemented. Moreover, disparities in access to specialized neonatal toxicology care create barriers to effective management, particularly in low-resource settings where healthcare infrastructure is limited. Addressing these challenges requires a multi-pronged approach, including enhanced toxicology screening programs, improved access to treatment, and the development of safer drug therapies specifically designed for neonates.

Can Emerging Technologies Revolutionize Neonatal Toxicology?

The neonatal toxicology market is witnessing a wave of technological advancements aimed at improving detection, diagnosis, and treatment outcomes. One of the most significant innovations is the development of high-throughput screening methods that allow for rapid identification of toxic substances in neonatal biological samples. Liquid chromatography-mass spectrometry (LC-MS) and gas chromatography-mass spectrometry (GC-MS) are increasingly being used for precise toxicological analysis, enabling early intervention in cases of in-utero drug exposure or environmental contamination. Another breakthrough is the introduction of non-invasive toxicology screening techniques, such as dried blood spot analysis and breath-based biomarkers, which minimize discomfort for newborns while providing critical diagnostic information. Artificial intelligence and machine learning are also being integrated into neonatal toxicology, enhancing predictive models for neonatal drug metabolism and toxic exposure risks. Additionally, advancements in neonatal pharmacogenomics are paving the way for personalized medicine approaches, optimizing drug dosing and minimizing adverse reactions in newborns. Digital health platforms and remote monitoring technologies are further supporting neonatal toxicology, allowing real-time tracking of neonatal health indicators and toxic exposure markers. As these innovations continue to reshape neonatal care, the potential for improved neonatal toxicology outcomes is expanding, offering new hope for safer and more effective management of toxic exposures in newborns.

What Is Driving the Growth of the Neonatal Toxicology Market?

The growth in the neonatal toxicology market is driven by several factors, including the increasing prevalence of neonatal substance exposure, heightened awareness of environmental toxins, and advancements in diagnostic and therapeutic technologies. The global rise in opioid addiction and substance abuse during pregnancy has fueled demand for neonatal toxicology services, with healthcare providers seeking improved screening and treatment strategies for affected newborns. Government initiatives aimed at combating neonatal drug exposure, such as enhanced prenatal screening programs and neonatal withdrawal management protocols, are also propelling market expansion. The growing emphasis on environmental health and its impact on neonatal development has led to increased research and regulatory measures addressing prenatal and postnatal toxic exposures. Moreover, the expansion of neonatal intensive care units (NICUs) and specialized pediatric toxicology centers is further contributing to market growth. Technological advancements, including next-generation toxicology screening platforms and AI-driven neonatal risk assessment tools, are enhancing diagnostic accuracy and treatment efficiency. Additionally, the increasing collaboration between pharmaceutical companies, healthcare institutions, and research organizations is fostering the development of safer neonatal medications and treatment protocols. As neonatal toxicology continues to evolve, its role in safeguarding newborn health is becoming more prominent, driving sustained market growth and shaping the future of neonatal healthcare.

SCOPE OF STUDY:

The report analyzes the Neonatal Toxicology market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Specimen Type (Meconium, Urine, Umbilical Cord, Other Specimen Types); Technology Type (Mass Spectroscopy Technology, Immunoassay Technology); Drug Type (Cannabinoids, Opioids, Cocaine, Benzodiazepines, Amphetamines, Other Illicit Drug Types); End-Use (Clinical Laboratories End-Use, Hospitals End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 37 Featured) -

• Agilent Technologies, Inc.
• ARUP Laboratories
• Bio-Rad Laboratories, Inc.
• Charles River Laboratories
• Cordant Health Solutions
• Covance Inc.
• ERBC Group
• Eurofins Scientific
• ICON plc
• Labcorp
• Medpace Holdings, Inc.
• NMS Labs
• Omega Laboratories, Inc.
• Parexel International Corporation
• PPD, Inc.
• PRA Health Sciences
• Quest Diagnostics Incorporated
• Syneos Health
• USDTL (United States Drug Testing Laboratories, Inc.)
• WuXi AppTec

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Neonatal Toxicology - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rise in Neonatal ICU Admissions Propels Growth of Targeted Toxicological Screening Solutions
  • Increasing Incidence of In-Utero Drug Exposure Throws the Spotlight on Neonatal Toxicology Testing
  • Growing Emphasis on Early Diagnosis Expands Addressable Market Opportunity for Neonatal Toxicology Tools
  • Surge in Prescription and Illicit Drug Use Among Pregnant Women Accelerates Demand for Neonatal Toxicology Services
  • Integration of Mass Spectrometry and Advanced Chromatography Techniques Strengthens Business Case for High-Precision Neonatal Screening
  • Push Towards Universal Drug Screening Protocols Drives Adoption of Standardized Neonatal Testing Kits
  • Rising Regulatory Mandates and Hospital Accreditation Requirements Spur Compliance-Driven Demand
  • Growth in Neonatal Research Funding Sustains Long-Term Market Expansion
  • Expansion of Telehealth and Remote Diagnostic Capabilities Enhances Reach of Neonatal Toxicology Programs
  • Advances in Micro-Sample Collection Techniques Drive Growth in Minimally Invasive Neonatal Testing
  • Increasing Collaboration Between Public Health Agencies and Hospitals Propels Market Awareness and Accessibility
  • Growing Awareness of Neonatal Abstinence Syndrome (NAS) Drives Demand for Early Toxicological Detection
  • Shift Towards Personalized Neonatal Care Strengthens Business Case for Tailored Toxicology Panels
  • Rapid Adoption of AI-Powered Diagnostic Tools Generates Opportunities in Automated Toxicology Screening
  • Rising Prevalence of Polysubstance Abuse Among Pregnant Women Expands Need for Broad-Spectrum Testing Solutions
  • Innovation in Point-of-Care Testing (POCT) Technologies Accelerates Adoption in Neonatal Care Units
  • Expansion of Hospital Infrastructure in Emerging Markets Unlocks New Growth Frontiers
  • Increasing Focus on Data Integration and Real-Time Monitoring Drives Demand for Interoperable Toxicology Platforms
  • Growing Payer Support for Early Toxicological Intervention Enhances Reimbursement Landscape
  • Ethical and Legal Pressures on Hospitals and Health Systems Create Imperatives for Rigorous Neonatal Drug Testing
  • Standardization of Laboratory Protocols Across Regions Strengthens Global Market Viability
  • Emergence of Cloud-Based Laboratory Information Systems (LIS) Spurs Digital Transformation in Neonatal Toxicology
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Neonatal Toxicology Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Neonatal Toxicology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Neonatal Toxicology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Neonatal Toxicology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Meconium by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Meconium by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Meconium by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Urine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Urine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Urine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Umbilical Cord by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Umbilical Cord by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Umbilical Cord by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Specimen Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Specimen Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Other Specimen Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Benzodiazepines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Benzodiazepines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Benzodiazepines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Amphetamines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Amphetamines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Amphetamines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other Illicit Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other Illicit Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Other Illicit Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Cannabinoids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Cannabinoids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Cannabinoids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Opioids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Opioids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Opioids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Cocaine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Cocaine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Cocaine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Clinical Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Clinical Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Clinical Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Mass Spectroscopy Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Mass Spectroscopy Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Mass Spectroscopy Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Immunoassay Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Immunoassay Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: World 15-Year Perspective for Immunoassay Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Neonatal Toxicology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 50: USA Recent Past, Current & Future Analysis for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: USA 15-Year Perspective for Neonatal Toxicology by Specimen Type - Percentage Breakdown of Value Sales for Meconium, Urine, Umbilical Cord and Other Specimen Types for the Years 2015, 2025 & 2030
  • TABLE 53: USA Recent Past, Current & Future Analysis for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: USA 15-Year Perspective for Neonatal Toxicology by Drug Type - Percentage Breakdown of Value Sales for Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine for the Years 2015, 2025 & 2030
  • TABLE 56: USA Recent Past, Current & Future Analysis for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: USA 15-Year Perspective for Neonatal Toxicology by End-Use - Percentage Breakdown of Value Sales for Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 59: USA Recent Past, Current & Future Analysis for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: USA Historic Review for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: USA 15-Year Perspective for Neonatal Toxicology by Technology Type - Percentage Breakdown of Value Sales for Mass Spectroscopy Technology and Immunoassay Technology for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: Canada 15-Year Perspective for Neonatal Toxicology by Specimen Type - Percentage Breakdown of Value Sales for Meconium, Urine, Umbilical Cord and Other Specimen Types for the Years 2015, 2025 & 2030
  • TABLE 65: Canada Recent Past, Current & Future Analysis for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: Canada 15-Year Perspective for Neonatal Toxicology by Drug Type - Percentage Breakdown of Value Sales for Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine for the Years 2015, 2025 & 2030
  • TABLE 68: Canada Recent Past, Current & Future Analysis for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Canada Historic Review for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: Canada 15-Year Perspective for Neonatal Toxicology by End-Use - Percentage Breakdown of Value Sales for Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 71: Canada Recent Past, Current & Future Analysis for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Canada Historic Review for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: Canada 15-Year Perspective for Neonatal Toxicology by Technology Type - Percentage Breakdown of Value Sales for Mass Spectroscopy Technology and Immunoassay Technology for the Years 2015, 2025 & 2030
• JAPAN
  • Neonatal Toxicology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 74: Japan Recent Past, Current & Future Analysis for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Japan Historic Review for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: Japan 15-Year Perspective for Neonatal Toxicology by Specimen Type - Percentage Breakdown of Value Sales for Meconium, Urine, Umbilical Cord and Other Specimen Types for the Years 2015, 2025 & 2030
  • TABLE 77: Japan Recent Past, Current & Future Analysis for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Japan Historic Review for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: Japan 15-Year Perspective for Neonatal Toxicology by Drug Type - Percentage Breakdown of Value Sales for Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine for the Years 2015, 2025 & 2030
  • TABLE 80: Japan Recent Past, Current & Future Analysis for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Japan Historic Review for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: Japan 15-Year Perspective for Neonatal Toxicology by End-Use - Percentage Breakdown of Value Sales for Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 83: Japan Recent Past, Current & Future Analysis for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Japan Historic Review for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: Japan 15-Year Perspective for Neonatal Toxicology by Technology Type - Percentage Breakdown of Value Sales for Mass Spectroscopy Technology and Immunoassay Technology for the Years 2015, 2025 & 2030
• CHINA
  • Neonatal Toxicology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 86: China Recent Past, Current & Future Analysis for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: China Historic Review for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: China 15-Year Perspective for Neonatal Toxicology by Specimen Type - Percentage Breakdown of Value Sales for Meconium, Urine, Umbilical Cord and Other Specimen Types for the Years 2015, 2025 & 2030
  • TABLE 89: China Recent Past, Current & Future Analysis for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: China Historic Review for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: China 15-Year Perspective for Neonatal Toxicology by Drug Type - Percentage Breakdown of Value Sales for Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine for the Years 2015, 2025 & 2030
  • TABLE 92: China Recent Past, Current & Future Analysis for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: China Historic Review for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: China 15-Year Perspective for Neonatal Toxicology by End-Use - Percentage Breakdown of Value Sales for Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 95: China Recent Past, Current & Future Analysis for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: China Historic Review for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: China 15-Year Perspective for Neonatal Toxicology by Technology Type - Percentage Breakdown of Value Sales for Mass Spectroscopy Technology and Immunoassay Technology for the Years 2015, 2025 & 2030
• EUROPE
  • Neonatal Toxicology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 98: Europe Recent Past, Current & Future Analysis for Neonatal Toxicology by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 99: Europe Historic Review for Neonatal Toxicology by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: Europe 15-Year Perspective for Neonatal Toxicology by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 101: Europe Recent Past, Current & Future Analysis for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Europe Historic Review for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: Europe 15-Year Perspective for Neonatal Toxicology by Specimen Type - Percentage Breakdown of Value Sales for Meconium, Urine, Umbilical Cord and Other Specimen Types for the Years 2015, 2025 & 2030
  • TABLE 104: Europe Recent Past, Current & Future Analysis for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Europe Historic Review for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: Europe 15-Year Perspective for Neonatal Toxicology by Drug Type - Percentage Breakdown of Value Sales for Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine for the Years 2015, 2025 & 2030
  • TABLE 107: Europe Recent Past, Current & Future Analysis for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Europe Historic Review for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: Europe 15-Year Perspective for Neonatal Toxicology by End-Use - Percentage Breakdown of Value Sales for Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 110: Europe Recent Past, Current & Future Analysis for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Europe Historic Review for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: Europe 15-Year Perspective for Neonatal Toxicology by Technology Type - Percentage Breakdown of Value Sales for Mass Spectroscopy Technology and Immunoassay Technology for the Years 2015, 2025 & 2030
• FRANCE
  • Neonatal Toxicology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 113: France Recent Past, Current & Future Analysis for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: France Historic Review for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: France 15-Year Perspective for Neonatal Toxicology by Specimen Type - Percentage Breakdown of Value Sales for Meconium, Urine, Umbilical Cord and Other Specimen Types for the Years 2015, 2025 & 2030
  • TABLE 116: France Recent Past, Current & Future Analysis for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: France Historic Review for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: France 15-Year Perspective for Neonatal Toxicology by Drug Type - Percentage Breakdown of Value Sales for Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine for the Years 2015, 2025 & 2030
  • TABLE 119: France Recent Past, Current & Future Analysis for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: France Historic Review for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: France 15-Year Perspective for Neonatal Toxicology by End-Use - Percentage Breakdown of Value Sales for Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 122: France Recent Past, Current & Future Analysis for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: France Historic Review for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: France 15-Year Perspective for Neonatal Toxicology by Technology Type - Percentage Breakdown of Value Sales for Mass Spectroscopy Technology and Immunoassay Technology for the Years 2015, 2025 & 2030
• GERMANY
  • Neonatal Toxicology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 125: Germany Recent Past, Current & Future Analysis for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Germany Historic Review for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: Germany 15-Year Perspective for Neonatal Toxicology by Specimen Type - Percentage Breakdown of Value Sales for Meconium, Urine, Umbilical Cord and Other Specimen Types for the Years 2015, 2025 & 2030
  • TABLE 128: Germany Recent Past, Current & Future Analysis for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Germany Historic Review for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: Germany 15-Year Perspective for Neonatal Toxicology by Drug Type - Percentage Breakdown of Value Sales for Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine for the Years 2015, 2025 & 2030
  • TABLE 131: Germany Recent Past, Current & Future Analysis for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Germany Historic Review for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: Germany 15-Year Perspective for Neonatal Toxicology by End-Use - Percentage Breakdown of Value Sales for Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 134: Germany Recent Past, Current & Future Analysis for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Germany Historic Review for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: Germany 15-Year Perspective for Neonatal Toxicology by Technology Type - Percentage Breakdown of Value Sales for Mass Spectroscopy Technology and Immunoassay Technology for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 137: Italy Recent Past, Current & Future Analysis for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Italy Historic Review for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: Italy 15-Year Perspective for Neonatal Toxicology by Specimen Type - Percentage Breakdown of Value Sales for Meconium, Urine, Umbilical Cord and Other Specimen Types for the Years 2015, 2025 & 2030
  • TABLE 140: Italy Recent Past, Current & Future Analysis for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Italy Historic Review for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: Italy 15-Year Perspective for Neonatal Toxicology by Drug Type - Percentage Breakdown of Value Sales for Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine for the Years 2015, 2025 & 2030
  • TABLE 143: Italy Recent Past, Current & Future Analysis for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Italy Historic Review for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: Italy 15-Year Perspective for Neonatal Toxicology by End-Use - Percentage Breakdown of Value Sales for Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 146: Italy Recent Past, Current & Future Analysis for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Italy Historic Review for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: Italy 15-Year Perspective for Neonatal Toxicology by Technology Type - Percentage Breakdown of Value Sales for Mass Spectroscopy Technology and Immunoassay Technology for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Neonatal Toxicology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 149: UK Recent Past, Current & Future Analysis for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: UK Historic Review for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: UK 15-Year Perspective for Neonatal Toxicology by Specimen Type - Percentage Breakdown of Value Sales for Meconium, Urine, Umbilical Cord and Other Specimen Types for the Years 2015, 2025 & 2030
  • TABLE 152: UK Recent Past, Current & Future Analysis for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: UK Historic Review for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: UK 15-Year Perspective for Neonatal Toxicology by Drug Type - Percentage Breakdown of Value Sales for Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine for the Years 2015, 2025 & 2030
  • TABLE 155: UK Recent Past, Current & Future Analysis for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: UK Historic Review for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: UK 15-Year Perspective for Neonatal Toxicology by End-Use - Percentage Breakdown of Value Sales for Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 158: UK Recent Past, Current & Future Analysis for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: UK Historic Review for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: UK 15-Year Perspective for Neonatal Toxicology by Technology Type - Percentage Breakdown of Value Sales for Mass Spectroscopy Technology and Immunoassay Technology for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 161: Spain Recent Past, Current & Future Analysis for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Spain Historic Review for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: Spain 15-Year Perspective for Neonatal Toxicology by Specimen Type - Percentage Breakdown of Value Sales for Meconium, Urine, Umbilical Cord and Other Specimen Types for the Years 2015, 2025 & 2030
  • TABLE 164: Spain Recent Past, Current & Future Analysis for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Spain Historic Review for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: Spain 15-Year Perspective for Neonatal Toxicology by Drug Type - Percentage Breakdown of Value Sales for Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine for the Years 2015, 2025 & 2030
  • TABLE 167: Spain Recent Past, Current & Future Analysis for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Spain Historic Review for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: Spain 15-Year Perspective for Neonatal Toxicology by End-Use - Percentage Breakdown of Value Sales for Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 170: Spain Recent Past, Current & Future Analysis for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Spain Historic Review for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: Spain 15-Year Perspective for Neonatal Toxicology by Technology Type - Percentage Breakdown of Value Sales for Mass Spectroscopy Technology and Immunoassay Technology for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 173: Russia Recent Past, Current & Future Analysis for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Russia Historic Review for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: Russia 15-Year Perspective for Neonatal Toxicology by Specimen Type - Percentage Breakdown of Value Sales for Meconium, Urine, Umbilical Cord and Other Specimen Types for the Years 2015, 2025 & 2030
  • TABLE 176: Russia Recent Past, Current & Future Analysis for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Russia Historic Review for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: Russia 15-Year Perspective for Neonatal Toxicology by Drug Type - Percentage Breakdown of Value Sales for Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine for the Years 2015, 2025 & 2030
  • TABLE 179: Russia Recent Past, Current & Future Analysis for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Russia Historic Review for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: Russia 15-Year Perspective for Neonatal Toxicology by End-Use - Percentage Breakdown of Value Sales for Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 182: Russia Recent Past, Current & Future Analysis for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Russia Historic Review for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: Russia 15-Year Perspective for Neonatal Toxicology by Technology Type - Percentage Breakdown of Value Sales for Mass Spectroscopy Technology and Immunoassay Technology for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Europe Historic Review for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Europe 15-Year Perspective for Neonatal Toxicology by Specimen Type - Percentage Breakdown of Value Sales for Meconium, Urine, Umbilical Cord and Other Specimen Types for the Years 2015, 2025 & 2030
  • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Europe Historic Review for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Europe 15-Year Perspective for Neonatal Toxicology by Drug Type - Percentage Breakdown of Value Sales for Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Europe Historic Review for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Europe 15-Year Perspective for Neonatal Toxicology by End-Use - Percentage Breakdown of Value Sales for Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Europe Recent Past, Current & Future Analysis for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Europe Historic Review for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Europe 15-Year Perspective for Neonatal Toxicology by Technology Type - Percentage Breakdown of Value Sales for Mass Spectroscopy Technology and Immunoassay Technology for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Neonatal Toxicology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Neonatal Toxicology by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 198: Asia-Pacific Historic Review for Neonatal Toxicology by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: Asia-Pacific 15-Year Perspective for Neonatal Toxicology by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Asia-Pacific Historic Review for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: Asia-Pacific 15-Year Perspective for Neonatal Toxicology by Specimen Type - Percentage Breakdown of Value Sales for Meconium, Urine, Umbilical Cord and Other Specimen Types for the Years 2015, 2025 & 2030
  • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Asia-Pacific Historic Review for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: Asia-Pacific 15-Year Perspective for Neonatal Toxicology by Drug Type - Percentage Breakdown of Value Sales for Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine for the Years 2015, 2025 & 2030
  • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Asia-Pacific Historic Review for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Asia-Pacific 15-Year Perspective for Neonatal Toxicology by End-Use - Percentage Breakdown of Value Sales for Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Asia-Pacific Historic Review for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: Asia-Pacific 15-Year Perspective for Neonatal Toxicology by Technology Type - Percentage Breakdown of Value Sales for Mass Spectroscopy Technology and Immunoassay Technology for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Neonatal Toxicology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 212: Australia Recent Past, Current & Future Analysis for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Australia Historic Review for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: Australia 15-Year Perspective for Neonatal Toxicology by Specimen Type - Percentage Breakdown of Value Sales for Meconium, Urine, Umbilical Cord and Other Specimen Types for the Years 2015, 2025 & 2030
  • TABLE 215: Australia Recent Past, Current & Future Analysis for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Australia Historic Review for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 217: Australia 15-Year Perspective for Neonatal Toxicology by Drug Type - Percentage Breakdown of Value Sales for Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine for the Years 2015, 2025 & 2030
  • TABLE 218: Australia Recent Past, Current & Future Analysis for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Australia Historic Review for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 220: Australia 15-Year Perspective for Neonatal Toxicology by End-Use - Percentage Breakdown of Value Sales for Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 221: Australia Recent Past, Current & Future Analysis for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Australia Historic Review for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 223: Australia 15-Year Perspective for Neonatal Toxicology by Technology Type - Percentage Breakdown of Value Sales for Mass Spectroscopy Technology and Immunoassay Technology for the Years 2015, 2025 & 2030
• INDIA
  • Neonatal Toxicology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 224: India Recent Past, Current & Future Analysis for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: India Historic Review for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 226: India 15-Year Perspective for Neonatal Toxicology by Specimen Type - Percentage Breakdown of Value Sales for Meconium, Urine, Umbilical Cord and Other Specimen Types for the Years 2015, 2025 & 2030
  • TABLE 227: India Recent Past, Current & Future Analysis for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: India Historic Review for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 229: India 15-Year Perspective for Neonatal Toxicology by Drug Type - Percentage Breakdown of Value Sales for Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine for the Years 2015, 2025 & 2030
  • TABLE 230: India Recent Past, Current & Future Analysis for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: India Historic Review for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 232: India 15-Year Perspective for Neonatal Toxicology by End-Use - Percentage Breakdown of Value Sales for Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 233: India Recent Past, Current & Future Analysis for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: India Historic Review for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 235: India 15-Year Perspective for Neonatal Toxicology by Technology Type - Percentage Breakdown of Value Sales for Mass Spectroscopy Technology and Immunoassay Technology for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 236: South Korea Recent Past, Current & Future Analysis for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: South Korea Historic Review for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 238: South Korea 15-Year Perspective for Neonatal Toxicology by Specimen Type - Percentage Breakdown of Value Sales for Meconium, Urine, Umbilical Cord and Other Specimen Types for the Years 2015, 2025 & 2030
  • TABLE 239: South Korea Recent Past, Current & Future Analysis for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: South Korea Historic Review for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 241: South Korea 15-Year Perspective for Neonatal Toxicology by Drug Type - Percentage Breakdown of Value Sales for Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine for the Years 2015, 2025 & 2030
  • TABLE 242: South Korea Recent Past, Current & Future Analysis for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: South Korea Historic Review for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 244: South Korea 15-Year Perspective for Neonatal Toxicology by End-Use - Percentage Breakdown of Value Sales for Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 245: South Korea Recent Past, Current & Future Analysis for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: South Korea Historic Review for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 247: South Korea 15-Year Perspective for Neonatal Toxicology by Technology Type - Percentage Breakdown of Value Sales for Mass Spectroscopy Technology and Immunoassay Technology for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Asia-Pacific Historic Review for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 250: Rest of Asia-Pacific 15-Year Perspective for Neonatal Toxicology by Specimen Type - Percentage Breakdown of Value Sales for Meconium, Urine, Umbilical Cord and Other Specimen Types for the Years 2015, 2025 & 2030
  • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Rest of Asia-Pacific Historic Review for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 253: Rest of Asia-Pacific 15-Year Perspective for Neonatal Toxicology by Drug Type - Percentage Breakdown of Value Sales for Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine for the Years 2015, 2025 & 2030
  • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Rest of Asia-Pacific Historic Review for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 256: Rest of Asia-Pacific 15-Year Perspective for Neonatal Toxicology by End-Use - Percentage Breakdown of Value Sales for Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 257: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Rest of Asia-Pacific Historic Review for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 259: Rest of Asia-Pacific 15-Year Perspective for Neonatal Toxicology by Technology Type - Percentage Breakdown of Value Sales for Mass Spectroscopy Technology and Immunoassay Technology for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Neonatal Toxicology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 260: Latin America Recent Past, Current & Future Analysis for Neonatal Toxicology by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 261: Latin America Historic Review for Neonatal Toxicology by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 262: Latin America 15-Year Perspective for Neonatal Toxicology by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 263: Latin America Recent Past, Current & Future Analysis for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Latin America Historic Review for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 265: Latin America 15-Year Perspective for Neonatal Toxicology by Specimen Type - Percentage Breakdown of Value Sales for Meconium, Urine, Umbilical Cord and Other Specimen Types for the Years 2015, 2025 & 2030
  • TABLE 266: Latin America Recent Past, Current & Future Analysis for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Latin America Historic Review for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 268: Latin America 15-Year Perspective for Neonatal Toxicology by Drug Type - Percentage Breakdown of Value Sales for Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine for the Years 2015, 2025 & 2030
  • TABLE 269: Latin America Recent Past, Current & Future Analysis for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Latin America Historic Review for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 271: Latin America 15-Year Perspective for Neonatal Toxicology by End-Use - Percentage Breakdown of Value Sales for Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 272: Latin America Recent Past, Current & Future Analysis for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Latin America Historic Review for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 274: Latin America 15-Year Perspective for Neonatal Toxicology by Technology Type - Percentage Breakdown of Value Sales for Mass Spectroscopy Technology and Immunoassay Technology for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 275: Argentina Recent Past, Current & Future Analysis for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Argentina Historic Review for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 277: Argentina 15-Year Perspective for Neonatal Toxicology by Specimen Type - Percentage Breakdown of Value Sales for Meconium, Urine, Umbilical Cord and Other Specimen Types for the Years 2015, 2025 & 2030
  • TABLE 278: Argentina Recent Past, Current & Future Analysis for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Argentina Historic Review for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 280: Argentina 15-Year Perspective for Neonatal Toxicology by Drug Type - Percentage Breakdown of Value Sales for Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine for the Years 2015, 2025 & 2030
  • TABLE 281: Argentina Recent Past, Current & Future Analysis for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Argentina Historic Review for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 283: Argentina 15-Year Perspective for Neonatal Toxicology by End-Use - Percentage Breakdown of Value Sales for Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 284: Argentina Recent Past, Current & Future Analysis for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Argentina Historic Review for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 286: Argentina 15-Year Perspective for Neonatal Toxicology by Technology Type - Percentage Breakdown of Value Sales for Mass Spectroscopy Technology and Immunoassay Technology for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 287: Brazil Recent Past, Current & Future Analysis for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Brazil Historic Review for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 289: Brazil 15-Year Perspective for Neonatal Toxicology by Specimen Type - Percentage Breakdown of Value Sales for Meconium, Urine, Umbilical Cord and Other Specimen Types for the Years 2015, 2025 & 2030
  • TABLE 290: Brazil Recent Past, Current & Future Analysis for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Brazil Historic Review for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 292: Brazil 15-Year Perspective for Neonatal Toxicology by Drug Type - Percentage Breakdown of Value Sales for Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine for the Years 2015, 2025 & 2030
  • TABLE 293: Brazil Recent Past, Current & Future Analysis for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Brazil Historic Review for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 295: Brazil 15-Year Perspective for Neonatal Toxicology by End-Use - Percentage Breakdown of Value Sales for Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 296: Brazil Recent Past, Current & Future Analysis for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Brazil Historic Review for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 298: Brazil 15-Year Perspective for Neonatal Toxicology by Technology Type - Percentage Breakdown of Value Sales for Mass Spectroscopy Technology and Immunoassay Technology for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 299: Mexico Recent Past, Current & Future Analysis for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Mexico Historic Review for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 301: Mexico 15-Year Perspective for Neonatal Toxicology by Specimen Type - Percentage Breakdown of Value Sales for Meconium, Urine, Umbilical Cord and Other Specimen Types for the Years 2015, 2025 & 2030
  • TABLE 302: Mexico Recent Past, Current & Future Analysis for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Mexico Historic Review for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 304: Mexico 15-Year Perspective for Neonatal Toxicology by Drug Type - Percentage Breakdown of Value Sales for Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine for the Years 2015, 2025 & 2030
  • TABLE 305: Mexico Recent Past, Current & Future Analysis for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Mexico Historic Review for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 307: Mexico 15-Year Perspective for Neonatal Toxicology by End-Use - Percentage Breakdown of Value Sales for Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 308: Mexico Recent Past, Current & Future Analysis for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Mexico Historic Review for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 310: Mexico 15-Year Perspective for Neonatal Toxicology by Technology Type - Percentage Breakdown of Value Sales for Mass Spectroscopy Technology and Immunoassay Technology for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Rest of Latin America Historic Review for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 313: Rest of Latin America 15-Year Perspective for Neonatal Toxicology by Specimen Type - Percentage Breakdown of Value Sales for Meconium, Urine, Umbilical Cord and Other Specimen Types for the Years 2015, 2025 & 2030
  • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Rest of Latin America Historic Review for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 316: Rest of Latin America 15-Year Perspective for Neonatal Toxicology by Drug Type - Percentage Breakdown of Value Sales for Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine for the Years 2015, 2025 & 2030
  • TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Rest of Latin America Historic Review for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 319: Rest of Latin America 15-Year Perspective for Neonatal Toxicology by End-Use - Percentage Breakdown of Value Sales for Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 320: Rest of Latin America Recent Past, Current & Future Analysis for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Rest of Latin America Historic Review for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 322: Rest of Latin America 15-Year Perspective for Neonatal Toxicology by Technology Type - Percentage Breakdown of Value Sales for Mass Spectroscopy Technology and Immunoassay Technology for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Neonatal Toxicology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 323: Middle East Recent Past, Current & Future Analysis for Neonatal Toxicology by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 324: Middle East Historic Review for Neonatal Toxicology by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 325: Middle East 15-Year Perspective for Neonatal Toxicology by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 326: Middle East Recent Past, Current & Future Analysis for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Middle East Historic Review for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 328: Middle East 15-Year Perspective for Neonatal Toxicology by Specimen Type - Percentage Breakdown of Value Sales for Meconium, Urine, Umbilical Cord and Other Specimen Types for the Years 2015, 2025 & 2030
  • TABLE 329: Middle East Recent Past, Current & Future Analysis for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Middle East Historic Review for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 331: Middle East 15-Year Perspective for Neonatal Toxicology by Drug Type - Percentage Breakdown of Value Sales for Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine for the Years 2015, 2025 & 2030
  • TABLE 332: Middle East Recent Past, Current & Future Analysis for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Middle East Historic Review for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 334: Middle East 15-Year Perspective for Neonatal Toxicology by End-Use - Percentage Breakdown of Value Sales for Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 335: Middle East Recent Past, Current & Future Analysis for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Middle East Historic Review for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 337: Middle East 15-Year Perspective for Neonatal Toxicology by Technology Type - Percentage Breakdown of Value Sales for Mass Spectroscopy Technology and Immunoassay Technology for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 338: Iran Recent Past, Current & Future Analysis for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Iran Historic Review for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 340: Iran 15-Year Perspective for Neonatal Toxicology by Specimen Type - Percentage Breakdown of Value Sales for Meconium, Urine, Umbilical Cord and Other Specimen Types for the Years 2015, 2025 & 2030
  • TABLE 341: Iran Recent Past, Current & Future Analysis for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Iran Historic Review for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 343: Iran 15-Year Perspective for Neonatal Toxicology by Drug Type - Percentage Breakdown of Value Sales for Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine for the Years 2015, 2025 & 2030
  • TABLE 344: Iran Recent Past, Current & Future Analysis for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Iran Historic Review for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 346: Iran 15-Year Perspective for Neonatal Toxicology by End-Use - Percentage Breakdown of Value Sales for Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 347: Iran Recent Past, Current & Future Analysis for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Iran Historic Review for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 349: Iran 15-Year Perspective for Neonatal Toxicology by Technology Type - Percentage Breakdown of Value Sales for Mass Spectroscopy Technology and Immunoassay Technology for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 350: Israel Recent Past, Current & Future Analysis for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Israel Historic Review for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 352: Israel 15-Year Perspective for Neonatal Toxicology by Specimen Type - Percentage Breakdown of Value Sales for Meconium, Urine, Umbilical Cord and Other Specimen Types for the Years 2015, 2025 & 2030
  • TABLE 353: Israel Recent Past, Current & Future Analysis for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Israel Historic Review for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 355: Israel 15-Year Perspective for Neonatal Toxicology by Drug Type - Percentage Breakdown of Value Sales for Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine for the Years 2015, 2025 & 2030
  • TABLE 356: Israel Recent Past, Current & Future Analysis for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Israel Historic Review for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 358: Israel 15-Year Perspective for Neonatal Toxicology by End-Use - Percentage Breakdown of Value Sales for Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 359: Israel Recent Past, Current & Future Analysis for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Israel Historic Review for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 361: Israel 15-Year Perspective for Neonatal Toxicology by Technology Type - Percentage Breakdown of Value Sales for Mass Spectroscopy Technology and Immunoassay Technology for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Saudi Arabia Historic Review for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 364: Saudi Arabia 15-Year Perspective for Neonatal Toxicology by Specimen Type - Percentage Breakdown of Value Sales for Meconium, Urine, Umbilical Cord and Other Specimen Types for the Years 2015, 2025 & 2030
  • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Saudi Arabia Historic Review for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 367: Saudi Arabia 15-Year Perspective for Neonatal Toxicology by Drug Type - Percentage Breakdown of Value Sales for Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine for the Years 2015, 2025 & 2030
  • TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 369: Saudi Arabia Historic Review for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 370: Saudi Arabia 15-Year Perspective for Neonatal Toxicology by End-Use - Percentage Breakdown of Value Sales for Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 371: Saudi Arabia Recent Past, Current & Future Analysis for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 372: Saudi Arabia Historic Review for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 373: Saudi Arabia 15-Year Perspective for Neonatal Toxicology by Technology Type - Percentage Breakdown of Value Sales for Mass Spectroscopy Technology and Immunoassay Technology for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 374: UAE Recent Past, Current & Future Analysis for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 375: UAE Historic Review for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 376: UAE 15-Year Perspective for Neonatal Toxicology by Specimen Type - Percentage Breakdown of Value Sales for Meconium, Urine, Umbilical Cord and Other Specimen Types for the Years 2015, 2025 & 2030
  • TABLE 377: UAE Recent Past, Current & Future Analysis for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 378: UAE Historic Review for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 379: UAE 15-Year Perspective for Neonatal Toxicology by Drug Type - Percentage Breakdown of Value Sales for Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine for the Years 2015, 2025 & 2030
  • TABLE 380: UAE Recent Past, Current & Future Analysis for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 381: UAE Historic Review for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 382: UAE 15-Year Perspective for Neonatal Toxicology by End-Use - Percentage Breakdown of Value Sales for Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 383: UAE Recent Past, Current & Future Analysis for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 384: UAE Historic Review for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 385: UAE 15-Year Perspective for Neonatal Toxicology by Technology Type - Percentage Breakdown of Value Sales for Mass Spectroscopy Technology and Immunoassay Technology for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Rest of Middle East Historic Review for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 388: Rest of Middle East 15-Year Perspective for Neonatal Toxicology by Specimen Type - Percentage Breakdown of Value Sales for Meconium, Urine, Umbilical Cord and Other Specimen Types for the Years 2015, 2025 & 2030
  • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Rest of Middle East Historic Review for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 391: Rest of Middle East 15-Year Perspective for Neonatal Toxicology by Drug Type - Percentage Breakdown of Value Sales for Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine for the Years 2015, 2025 & 2030
  • TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Rest of Middle East Historic Review for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 394: Rest of Middle East 15-Year Perspective for Neonatal Toxicology by End-Use - Percentage Breakdown of Value Sales for Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 395: Rest of Middle East Recent Past, Current & Future Analysis for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Rest of Middle East Historic Review for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 397: Rest of Middle East 15-Year Perspective for Neonatal Toxicology by Technology Type - Percentage Breakdown of Value Sales for Mass Spectroscopy Technology and Immunoassay Technology for the Years 2015, 2025 & 2030
• AFRICA
  • Neonatal Toxicology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 398: Africa Recent Past, Current & Future Analysis for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Africa Historic Review for Neonatal Toxicology by Specimen Type - Meconium, Urine, Umbilical Cord and Other Specimen Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 400: Africa 15-Year Perspective for Neonatal Toxicology by Specimen Type - Percentage Breakdown of Value Sales for Meconium, Urine, Umbilical Cord and Other Specimen Types for the Years 2015, 2025 & 2030
  • TABLE 401: Africa Recent Past, Current & Future Analysis for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Africa Historic Review for Neonatal Toxicology by Drug Type - Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 403: Africa 15-Year Perspective for Neonatal Toxicology by Drug Type - Percentage Breakdown of Value Sales for Benzodiazepines, Amphetamines, Other Illicit Drug Types, Cannabinoids, Opioids and Cocaine for the Years 2015, 2025 & 2030
  • TABLE 404: Africa Recent Past, Current & Future Analysis for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 405: Africa Historic Review for Neonatal Toxicology by End-Use - Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 406: Africa 15-Year Perspective for Neonatal Toxicology by End-Use - Percentage Breakdown of Value Sales for Clinical Laboratories End-Use, Hospitals End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • TABLE 407: Africa Recent Past, Current & Future Analysis for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 408: Africa Historic Review for Neonatal Toxicology by Technology Type - Mass Spectroscopy Technology and Immunoassay Technology Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 409: Africa 15-Year Perspective for Neonatal Toxicology by Technology Type - Percentage Breakdown of Value Sales for Mass Spectroscopy Technology and Immunoassay Technology for the Years 2015, 2025 & 2030

IV. COMPETITION